Research paper Archives - The Office of Health Economics (OHE)

Search the Knowledge Hub

Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals

Cole, A., Towse, A., Lorgelly, P., and Sullivan, R.

Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward

Baltussen, R., Marsh, K., Thokala, P., Diaby, V., Castro, H., Cleemput, I., Garau, M., Iskrov, G., Olyaeemanesh, A., Mirelman, A., Mobinizadeh, M., Morton, A., Tringali, M., van Til, J., Valentim, J., Wagner, M., Youngkong, S., Zah, V., Toll, A., Jansen, M., Biklmakers, L., Oortwijn, W. and Broekhuizen, H.

Can We Really Compare and Aggregate PRO Data Between People and Settings? Implications for Multi-Country Clinical Trials and HTA

Devlin, N., Lorgelly, P. and Herdman, M.

New Methods for Analysing the Distribution of EQ-5D Observations

Zamora, B., Parkin, D., Feng, Y., Bateman, A., Herdman, M., and Devlin, N.

Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value

Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value

Marsden, G., Towse, A., Pearson, S.D., Dreitlein, B. and Henshall, C.

What is the Normative Basis for Selecting the Measure of ‘Average’ Preferences for Use in Social Choices?

Devlin, N., Shah, K.K., and Buckingham, K.

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Garau, M., Marsden, G., Devlin, N., Amedeo Mazzanti, N. and Profico, A.

Important Aspects of Health Not Captured by EQ-5D: Views of the UK General Public

Shah, K., Mulhern, B., Longworth, L. and Janssen, B.

Exploring the link between health and wealth in decision making

Exploring the link between health and wealth in decision making

Garau, M., Shah, K., Sharma, P. and Towse, A.

Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?

Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?

Garau, M., Towse, A., Garrison, L., Housman, L. and Ossa, D.

Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches

Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches

Sussex, J., Towse, A. and Devlin, N.

Get Technical Assistance